The FDA ordered manufacturers to pull all remaining Zantac (ranitidine) heartburn pills off store shelves due to unacceptable levels of a cancer-causing impurity.
As a growing number of lawsuits are filed by people with cancer, more recalls have been issued for prescription-strength ranitidine (generic over-the-counter Zantac®) due to the carcinogen NDMA.
More drug-makers have recalled prescription-strength and over-the-counter Zantac® and generic ranitidine heartburn pills, including stores like Walgreens, Walmart, CVS, Target, and Kroger.
GlaxoSmithKline (GSK) has issued a global recall for prescription-strength Zantac® heartburn medications due to "unacceptable" levels of a cancer-causing chemical in the pills.
Sandoz recalled generic Zantac (ranitidine) due to a potential risk of carcinogenic impurities.
A class action lawsuit accuses Sanofi of selling Zantac® heartburn drugs with 26,000-times the FDA-approved limit of NDMA, a cancer-causing chemical impurity.
The widely-prescribed heartburn medication Zantac (generic: ranitidine) has been found to contain N-nitrosodimethylamine, or NDMA, a known human carcinogen (cancer-causing substance), according to an FDA press release published on Friday.